Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo Aberto, de Braço Único, de Profilaxia para Estomatite Relacionada com Datopotamab Deruxtecan (Dato-DXd) em Doentes Elegíveis com Cancro da Mama Metastático ou Localmente Recorrente Inoperável ou Cancro do Pulmão de Não-Pequenas Células Localmente Avançado ou Metastático com Mutação do Recetor do Fator de Crescimento Epidérmico. (TROPION-SWISH)

27 de outubro de 2026 atualizado por: AstraZeneca

Um Estudo de Fase IV, Aberto, de Braço Único de Profilaxia para Estomatite Relacionada com Datopotamab Deruxtecan em Doentes Elegíveis com Cancro da Mama Metastático ou Localmente Recorrente Inoperável ou Cancro do Pulmão de Células Não Pequenas Localmente Avançado ou Metastático com Mutação do Recetor do Fator de Crescimento Epidérmico (TROPION-SWISH)

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The purpose of this Phase IV study is to describe the incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in participants receiving prophylactic dexamethasone mouthwash within the first 12 weeks of study treatment (ie, Dato-DXd dosing).

The study will enroll an estimated 100 participants across approximately 35 sites in the U.S. Enrollment of participants is planned to occur over approximately 18 months, with a minimum of 12 weeks of follow-up for each participant after the first Dato-DXd dose.

This study has one arm, and the study population will consist of 2 independent cohorts (approximately 50 participants in each cohort):

  • Breast cohort (Cohort 1)
  • Lung cohort (Cohort 2)

Participants will receive the study intervention, dexamethasone mouthwash, throughout the duration of their standard of care treatment with Dato-DXd.

Tipo de estudo

Intervencional

Inscrição (Estimado)

100

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Arizona
      • Tucson, Arizona, Estados Unidos, 85719
        • Retirado
        • Research Site
    • Arkansas
      • Hot Springs, Arkansas, Estados Unidos, 71913
        • Recrutamento
        • Research Site
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Recrutamento
        • Research Site
    • California
      • Duarte, California, Estados Unidos, 91010
        • Ainda não está recrutando
        • Research Site
      • Glendale, California, Estados Unidos, 91204
        • Recrutamento
        • Research Site
      • Lakewood, California, Estados Unidos, 90805
        • Recrutamento
        • Research Site
      • Long Beach, California, Estados Unidos, 90806
        • Recrutamento
        • Research Site
      • Torrance, California, Estados Unidos, 90505
        • Ainda não está recrutando
        • Research Site
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20037
        • Retirado
        • Research Site
    • Florida
      • Coral Springs, Florida, Estados Unidos, 33065
        • Recrutamento
        • Research Site
      • Plantation, Florida, Estados Unidos, 33322
        • Recrutamento
        • Research Site
    • Georgia
      • Athens, Georgia, Estados Unidos, 30607
        • Recrutamento
        • Research Site
    • Idaho
      • Boise, Idaho, Estados Unidos, 83706
        • Retirado
        • Research Site
    • Illinois
      • Park Ridge, Illinois, Estados Unidos, 60068
        • Retirado
        • Research Site
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46825
        • Recrutamento
        • Research Site
    • Kentucky
      • Elizabethtown, Kentucky, Estados Unidos, 42701
        • Recrutamento
        • Research Site
      • Lexington, Kentucky, Estados Unidos, 40503
        • Recrutamento
        • Research Site
      • Lexington, Kentucky, Estados Unidos, 40509
        • Ainda não está recrutando
        • Research Site
      • Louisville, Kentucky, Estados Unidos, 40207
        • Recrutamento
        • Research Site
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Ainda não está recrutando
        • Research Site
    • Maryland
      • Frederick, Maryland, Estados Unidos, 21702
        • Retirado
        • Research Site
      • Glenn Dale, Maryland, Estados Unidos, 20769
        • Ainda não está recrutando
        • Research Site
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Ainda não está recrutando
        • Research Site
      • Grayling, Michigan, Estados Unidos, 49738
        • Recrutamento
        • Research Site
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55426
        • Recrutamento
        • Research Site
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64111
        • Recrutamento
        • Research Site
    • Nevada
      • Reno, Nevada, Estados Unidos, 89502
        • Retirado
        • Research Site
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03756
        • Retirado
        • Research Site
    • New York
      • East Syracuse, New York, Estados Unidos, 13057
        • Recrutamento
        • Research Site
      • Westbury, New York, Estados Unidos, 11590
        • Ainda não está recrutando
        • Research Site
      • White Plains, New York, Estados Unidos, 10601
        • Retirado
        • Research Site
    • North Carolina
      • Greensboro, North Carolina, Estados Unidos, 27403
        • Ainda não está recrutando
        • Research Site
      • Wilson, North Carolina, Estados Unidos, 27893
        • Recrutamento
        • Research Site
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • Ainda não está recrutando
        • Research Site
    • Pennsylvania
      • Wynnewood, Pennsylvania, Estados Unidos, 19096
        • Recrutamento
        • Research Site
    • South Carolina
      • West Columbia, South Carolina, Estados Unidos, 29169
        • Ainda não está recrutando
        • Research Site
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37920
        • Recrutamento
        • Research Site
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Recrutamento
        • Research Site
    • West Virginia
      • Charleston, West Virginia, Estados Unidos, 25304
        • Retirado
        • Research Site
      • Morgantown, West Virginia, Estados Unidos, 26506
        • Recrutamento
        • Research Site
    • Wisconsin
      • Waukesha, Wisconsin, Estados Unidos, 53188
        • Recrutamento
        • Research Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Patients are eligible to be included in the study only if all the following criteria apply:

Disease Characteristics

  1. Patients with any of the following disease characteristics are eligible (specific population subject to FDA Dato-DXd label):

    • Patients with unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior ET and chemotherapy for unresectable or metastatic disease.

    OR

    • Adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Participants will be enrolled upon FDA approval on use of Dato-DXd for this indication.

    OR

    • Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.

    Age

  2. Patient must be ≥ 18 years, at the time of signing the informed consent.

    Type of Patient and Disease Characteristics-

  3. Has documentation that Dato-DXd will be prescribed for the labelled indication and has not received any dose of Dato-DXd prior to enrollment.

  4. Is willing to comply with use of prophylactic dexamethasone mouthwash at the start of first infusion and throughout Dato-DXd administration.

  5. ECOG performance status 0 or 1.

  6. Has adequate bone marrow function (hemoglobin ≥ 9 g/dL; red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).

  7. All women of childbearing potential must have a negative serum pregnancy test result at screening.

    Informed Consent

  8. Capable of giving signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the ICF and the protocol.

Exclusion Criteria:

Patients are excluded from the study if any of the following criteria apply:

  1. Has received Dato-DXd prior to enrollment.

    Medical Conditions

  2. As judged by the investigator, any evidence of cardiac, pulmonary, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the patient to participate in the study.

  3. Has any-grade active and uncontrolled stomatitis or mouth ulcers at baseline (participants with prior medical history of stomatitis or mouth ulcers are eligible).

  4. Use of steroid-containing mouthwash is contraindicated in, including but not limited to:

    • Active oral infections (eg, viral, bacterial, or fungal), where the use of a steroid-containing mouthwash may impair local immune response and delay healing
    • Known hypersensitivity or allergy to corticosteroids or any excipients contained in the mouthwash formulation
  5. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localized fungal infections of skin or nails are eligible).

  6. Has clinically significant corneal disease.

  7. Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients of Dato-DXd (including, but not limited to, polysorbate 80).

  8. Has a history of severe hypersensitivity reactions to other monoclonal antibodies.

  9. Is pregnant, or breastfeeding, or planning to become pregnant.

    Other Exclusions

  10. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

  11. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

  12. Previous enrollment in the present study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dexamethasone 0.5 mg/5 mL Mouthwash

Participants will use dexamethasone 0.5 mg/5 mL alcohol-free mouthwash (10 mL, 4 times daily, swish for approximately 2 minutes, then spit out without swallowing).

Participants will remain without food or drink for at least 30 minutes after use of dexamethasone

Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.

Commercially available Dato-DXd is prescribed and administered to participants according to standard of care

Outros nomes:
  • Datroway

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in patients receiving prophylactic dexamethasone mouthwash within first 12 weeks of study treatment
Prazo: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment

Incidence is defined as the proportion of participants who develop National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 grade ≥ 2 stomatitis accompanied by either a Normalcy of Diet Subscale score ≤ 50 and/or a Numeric Rating Scale (NRS) oral-pain score of 7 on 2 consecutive days or 8, 9, or 10 on any one day.

Severity will be based on the highest NCI-CTCAE v5.0 grade of stomatitis experienced by each participant.

CTCAE displays Grades 1-5 with descriptions of severity for each adverse event (AE). Grade 1 for mild symptoms and Grade 5 for death related to AE.

The Normalcy of Diet Subscale assesses the degree to which a patient can eat a normal diet and drink liquids. The scale is a ranking of 10 food categories, from easy-to-eat to difficult-to-eat.

The Numeric Rating Scale is a scale for self-reporting of pain. Scores range from 0-10, with higher scores meaning the worst pain possible (0=no pain to 10=worst possible pain).

From date of first dose of study treatment until 12 weeks after date of first dose of study treatment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis
Prazo: From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment

This will be determined using the composite stomatitis definition in the primary outcome. Will be repeated within 6 weeks and within 9 weeks of study treatment.

From date of first dose of study treatment until 6 and 9 weeks after date of first dose of study treatment
Incidence and severity of treatment-emergent stomatitis overall, by maximum CTCAE grade, and CTCAE grade ≥ 2
Prazo: From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment

This will be determined using stomatitis CTCAE grade only. Will be analysed at 6, 9 and 12 weeks.

From date of first dose of study treatment until 6, 9 and 12 weeks after date of first dose of study treatment
Time to onset of grade ≥ 2 stomatitis
Prazo: From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months

The time (in days) from the date of the first dose of Dato-DXd to the date of first onset to a grade ≥ 2 stomatitis event. The measure of primary interest is median time to onset.

From date of first dose until earliest of diagnosis of grade ≥2 stomatitis, Dato-DXD discontinuation and death, whichever occurs first, assessed up to approximately 21 months
Time to resolution of Dato-DXd-related grade ≥ 2 stomatitis
Prazo: From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months

Number of days from the date of onset of stomatitis grade ≥ 2 until the earliest date of event resolved or reduced in severity to grade 1. The measure of primary interest is median time to resolution.

From date of diagnosis of grade ≥2 stomatitis until the earliest date of event resolved or reduced in severity to grade 1, assessed up to approximately 21 months
Proportion of participants with a dose modification for Dato-DXd due to stomatitis
Prazo: From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months

Dose modification is defined as dose reduction, delay, or discontinuation due to stomatitis Treatment-Emergent Adverse Event (TEAE).

From date of first dose until earliest of Dato-DXD discontinuation and death, assessed up to approximately 21 months
Participant adherence to dexamethasone mouthwash
Prazo: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment

Adherence to dexamethasone mouthwash will be assessed by cohort using the Daily Activities Diary. The measure of primary interest is the median number of swished mouthwashes per day.

From date of first dose of study treatment until 12 weeks after date of first dose of study treatment
Safety and tolerability of Dato-DXd in participants receiving prophylactic dexamethasone mouthwash
Prazo: From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months

Safety and tolerability will be evaluated by cohort in terms of AEs (graded by NCI-CTCAE v5.0) and in terms of the following:

  • Incidence and severity of TEAEs and Serious Adverse Events (SAEs), including oral infections (such as fungal infections) associated with the use of the dexamethasone mouthwash
  • Eastern Cooperative Oncology Group (ECOG) performance status
  • Vital signs and physical examination
  • Clinical chemistry, hematology, urinalysis, and coagulation assessments
  • Use of antifungal medication for treating dexamethasone-related fungal infection.
From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up), approximately 21 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de junho de 2026

Conclusão Primária (Estimado)

4 de janeiro de 2028

Conclusão do estudo (Estimado)

4 de janeiro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

21 de janeiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de janeiro de 2026

Primeira postagem (Real)

22 de janeiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • D926UL00001

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Prazo de Compartilhamento de IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Critérios de acesso de compartilhamento IPD

When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .